ES2635382T3 - Utilización de un extracto de mirto como agente anti-biopelícula contra P. acnes - Google Patents
Utilización de un extracto de mirto como agente anti-biopelícula contra P. acnes Download PDFInfo
- Publication number
- ES2635382T3 ES2635382T3 ES13737198.5T ES13737198T ES2635382T3 ES 2635382 T3 ES2635382 T3 ES 2635382T3 ES 13737198 T ES13737198 T ES 13737198T ES 2635382 T3 ES2635382 T3 ES 2635382T3
- Authority
- ES
- Spain
- Prior art keywords
- composition
- biofilm
- extract
- acnes
- myrtle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 240000005125 Myrtus communis Species 0.000 title claims abstract description 77
- 235000013418 Myrtus communis Nutrition 0.000 title claims abstract description 76
- 241000186427 Cutibacterium acnes Species 0.000 title claims abstract description 73
- 230000003214 anti-biofilm Effects 0.000 title claims description 14
- 239000000203 mixture Substances 0.000 claims abstract description 39
- 241000894006 Bacteria Species 0.000 claims abstract description 38
- 229940055019 propionibacterium acne Drugs 0.000 claims abstract description 25
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 21
- 230000003115 biocidal effect Effects 0.000 claims abstract description 18
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 11
- 230000006378 damage Effects 0.000 claims abstract description 9
- 230000008029 eradication Effects 0.000 claims abstract description 7
- 230000000699 topical effect Effects 0.000 claims abstract description 7
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 16
- 206010000496 acne Diseases 0.000 claims description 16
- 238000011282 treatment Methods 0.000 claims description 14
- 206010016936 Folliculitis Diseases 0.000 claims description 8
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 claims description 7
- 229940096998 ursolic acid Drugs 0.000 claims description 7
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 claims description 7
- 230000003449 preventive effect Effects 0.000 claims description 4
- 239000013066 combination product Substances 0.000 claims description 3
- 229940127555 combination product Drugs 0.000 claims description 3
- 239000000047 product Substances 0.000 claims description 2
- 230000008521 reorganization Effects 0.000 claims description 2
- 230000007423 decrease Effects 0.000 abstract description 5
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 55
- 229960003276 erythromycin Drugs 0.000 description 24
- 230000000694 effects Effects 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 14
- 238000012360 testing method Methods 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 229940088710 antibiotic agent Drugs 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 6
- 230000032770 biofilm formation Effects 0.000 description 6
- 244000005700 microbiome Species 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 4
- 229940011051 isopropyl acetate Drugs 0.000 description 4
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 4
- 230000008520 organization Effects 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000004599 antimicrobial Substances 0.000 description 3
- 230000000712 assembly Effects 0.000 description 3
- 238000000429 assembly Methods 0.000 description 3
- 239000012620 biological material Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229960002227 clindamycin Drugs 0.000 description 3
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000012549 training Methods 0.000 description 3
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Natural products CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 235000019687 Lamb Nutrition 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 239000003139 biocide Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N dichloromethane Natural products ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229960003722 doxycycline Drugs 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N methyl pentane Natural products CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- 208000020154 Acnes Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 229920002306 Glycocalyx Polymers 0.000 description 1
- -1 Ketostearyl Isononanoate Chemical compound 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 208000035977 Rare disease Diseases 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 240000006661 Serenoa repens Species 0.000 description 1
- 235000005318 Serenoa repens Nutrition 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 229960003328 benzoyl peroxide Drugs 0.000 description 1
- 239000003364 biologic glue Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 210000000736 corneocyte Anatomy 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 210000004517 glycocalyx Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 231100001160 nonlethal Toxicity 0.000 description 1
- 230000037312 oily skin Effects 0.000 description 1
- 208000038009 orphan disease Diseases 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- WTGQALLALWYDJH-AKTDCHNFSA-N scopolamine hydrobromide Chemical class Br.C1([C@@H](CO)C(=O)OC2C[C@@H]3N([C@@H](C2)[C@H]2[C@@H]3O2)C)=CC=CC=C1 WTGQALLALWYDJH-AKTDCHNFSA-N 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Birds (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1256607 | 2012-07-09 | ||
| FR1256607A FR2992862B1 (fr) | 2012-07-09 | 2012-07-09 | Utilisation d'un extrait de myrte en tant qu'agent anti-biofilm vis-a-vis de p. acnes |
| PCT/EP2013/064415 WO2014009325A1 (fr) | 2012-07-09 | 2013-07-08 | Utilisation d'un extrait de myrte en tant qu'agent anti-biofilm vis-a-vis de p. acnes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2635382T3 true ES2635382T3 (es) | 2017-10-03 |
Family
ID=47022816
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13737198.5T Active ES2635382T3 (es) | 2012-07-09 | 2013-07-08 | Utilización de un extracto de mirto como agente anti-biopelícula contra P. acnes |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9808496B2 (https=) |
| EP (1) | EP2869827B1 (https=) |
| JP (1) | JP2015522054A (https=) |
| BR (1) | BR112015000275B1 (https=) |
| CA (1) | CA2878496C (https=) |
| ES (1) | ES2635382T3 (https=) |
| FR (1) | FR2992862B1 (https=) |
| MX (1) | MX355668B (https=) |
| WO (1) | WO2014009325A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101801521B (zh) | 2007-05-14 | 2015-06-17 | 纽约州立大学研究基金会 | 生物膜中细菌细胞内的生理学分散响应诱导 |
| MX2018008569A (es) | 2016-01-28 | 2018-08-16 | Kimberly Clark Co | Composicion antiadherente contra virus de acido desoxirribonucleico (adn) y metodo para inhibir la adherencia de virus de acido desoxirribonucleico (adn) a una superficie. |
| MX2018013276A (es) | 2016-05-26 | 2019-03-28 | Kimberly Clark Co | Composiciones antiadherentes y metodos para inhibir la adherencia de microbios a una superficie. |
| US11541105B2 (en) | 2018-06-01 | 2023-01-03 | The Research Foundation For The State University Of New York | Compositions and methods for disrupting biofilm formation and maintenance |
| FR3120790B1 (fr) | 2021-03-10 | 2024-03-15 | Fabre Pierre Dermo Cosmetique | Association d’un extrait de myrte et d’un extrait de Tripterygium wilfordii pour lutter contre l’inflammation induite par C. acnes |
| FR3132632B1 (fr) | 2022-02-17 | 2025-05-23 | Fabre Pierre Dermo Cosmetique | Composition comprenant un extrait de myrte et un extrait de Tripterygium wilfordii pour lutter contre l’acné des zones non lésionnelles de la peau acnéique |
| CN116763692A (zh) * | 2023-05-26 | 2023-09-19 | 广州凡岛网络科技有限公司 | 一种控油祛痘组合物及其应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2783425B1 (fr) | 1998-09-17 | 2002-06-07 | Fabre Pierre Dermo Cosmetique | Extrait de myrte titre en myrtucommulone b', son procede de preparation et son application en dermatologie et en cosmetologie |
| US20060008538A1 (en) * | 2004-07-07 | 2006-01-12 | Wu Jeffrey M | Methods of treating the skin |
| WO2012053010A2 (en) * | 2010-10-21 | 2012-04-26 | Cadila Healthcare Limited | Method for treatment of acne using pharmaceutical compositions of clindamycin |
-
2012
- 2012-07-09 FR FR1256607A patent/FR2992862B1/fr active Active
-
2013
- 2013-07-08 US US14/413,436 patent/US9808496B2/en active Active
- 2013-07-08 ES ES13737198.5T patent/ES2635382T3/es active Active
- 2013-07-08 JP JP2015520946A patent/JP2015522054A/ja active Pending
- 2013-07-08 MX MX2015000276A patent/MX355668B/es active IP Right Grant
- 2013-07-08 EP EP13737198.5A patent/EP2869827B1/fr active Active
- 2013-07-08 WO PCT/EP2013/064415 patent/WO2014009325A1/fr not_active Ceased
- 2013-07-08 CA CA2878496A patent/CA2878496C/fr active Active
- 2013-07-08 BR BR112015000275-7A patent/BR112015000275B1/pt active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014009325A1 (fr) | 2014-01-16 |
| FR2992862A1 (fr) | 2014-01-10 |
| EP2869827B1 (fr) | 2017-05-03 |
| CA2878496A1 (fr) | 2014-01-16 |
| JP2015522054A (ja) | 2015-08-03 |
| BR112015000275A2 (pt) | 2017-06-27 |
| BR112015000275B1 (pt) | 2021-02-09 |
| CA2878496C (fr) | 2020-12-15 |
| MX355668B (es) | 2018-04-24 |
| MX2015000276A (es) | 2015-07-21 |
| US9808496B2 (en) | 2017-11-07 |
| FR2992862B1 (fr) | 2014-10-03 |
| US20150190447A1 (en) | 2015-07-09 |
| EP2869827A1 (fr) | 2015-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2635382T3 (es) | Utilización de un extracto de mirto como agente anti-biopelícula contra P. acnes | |
| ES2441549T3 (es) | Antisépticos | |
| ES2907991T3 (es) | Composición de bacterias lácticas para el uso en el tratamiento de infecciones debidas a Propionibacterium acnes y en particular para el acné | |
| US10426747B2 (en) | Antimicrobials and methods of use thereof | |
| Li et al. | Phytochemical-based nanocomposites for the treatment of bacterial biofilms | |
| ES2726052T3 (es) | Composiciones que contienen ácido pirrolidona carboxílico (pca) y sales metálicas | |
| ES2560953T3 (es) | Extractos de plantas combinados para usar en el tratamiento de infecciones microbianas | |
| KR20100016450A (ko) | 피부 외용제 조성물 | |
| CN104540532A (zh) | 用于促进损伤的身体组织再生的包含作为活性物质的四氢嘧啶或羟基四氢嘧啶的组合物 | |
| US20140205586A1 (en) | Control of biofilm formation | |
| ES2588397T3 (es) | Composiciones con actividad antibacteriana y de curación de heridas | |
| FI124011B (fi) | Havupuun pihkan ja veden seos käytettäväksi antimikrobisena hoitoaineena ja antimikrobisena lisäaineena vesiohenteisissa liuoksissa | |
| US12447188B2 (en) | Compositions and methods for the antiseptic treatment of biofilms on mammalian tissue | |
| ES2703530T3 (es) | Composición cicatrizante y utilización | |
| Gaetti-Jardim Júnior et al. | Antimicrobial activity of six plant extracts from the Brazilian savanna on periodontal pathogens | |
| RU2401116C2 (ru) | Ранозаживляющий пробиотический препарат | |
| ES2438640B1 (es) | Composición para la regeneración y reparación de la piel | |
| US10398664B2 (en) | Methods of diagnosing and treating infected implants | |
| CN110090219A (zh) | 一种快速治疗牙疼和口腔炎症的药物及其制备方法 | |
| ES2926378T3 (es) | Compuestos para prevenir y tratar afecciones de la piel o mucosas que tienen un componente inflamatorio | |
| Alhasso | Development and Characterisation of Nanoemulsion and Nanoemulgel Formulations for Topical Application of mupirocin | |
| CA3106105A1 (en) | Methods of diagnosing and treating infected implants | |
| ES2749006T3 (es) | Composición médica teniendo actividad antibiótica, antiinflamatoria y de saneamiento de heridas | |
| Shinshal | Antibacterial effects of mixture (honey, Nigella sativa oil and propolis) on experimental animals infected with Pseudomonas aeruginosa | |
| BR102018072419A2 (pt) | Formulação de enxaguatório bucal do extrato de baccharis dracunculifolia com atividade antibacteriana |